Epicept and Myrexis Inc announced the initiation of a Phase 2b study of Azixa as a front-line treatment for glioblastoma multiforme (GBM). The controlled two-arm study will enroll up to 120 newly diagnosed GBM patients at treatment centers in the United States and India to evaluate and compare the standard of care in GBM with standard of care in combination with Azixa as a first-line GBM treatment.

Azixa is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies. Azixa is being evaluated in other Phase II trials, in metastatic melanoma in combination with temozolomide and in recurrent glioblastoma in combination with carboplatin.

For more information call (914) 606-3500 or visit www.epicept.com.